Pierini, Florencia S. http://orcid.org/0000-0002-9781-9535
Brom, Martin http://orcid.org/0000-0003-3960-3741
Scolnik, Marina
Scaglioni, Valeria
Rosa, Javier E.
Soriano, Enrique R.
Article History
Received: 21 August 2020
Accepted: 25 March 2021
First Online: 7 April 2021
Declarations
:
: This study was carried out in accordance with the Good Clinical Practice (GCP) guidelines, defined in the International Conference on Harmonization (ICH), and in accordance with the ethical principles detailed in the European Union Directive 2001/20 (EC) and the federal of the United States Code (Title 21, Part 50 (21CFR50). The study was approved by Institutional Review Board (IRB00010193, protocol #3518). Since this is a retrospective study, formal consent is not required.
: Not applicable.
: - Pierini M.D.; Brom M.D.; Scaglioni M.D.; Scolnik M.D. and Rosa M.D. declare no conflicts of interest.- Soriano M.D.: has received in the past speaker’s honorarium from AbbVie, Novartis, Bristol MS, Novartis, Eli Lilly, Genzyme, Pfizer, Amgen, and Roche. He is on the advisory board for Novartis, AbbVie, Pfizer, Eli Lilly, Sanofi, Sandoz, Amgen. He has received grant from Roche, Novartis, AbbVie, Glaxo Smith Kline.